ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1089

Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic
Abstract Number: 1090

Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center
Abstract Number: 1091

Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care
Abstract Number: 1092

Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous
Abstract Number: 1093

Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases
Abstract Number: 1094

“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis
Abstract Number: 1095

Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures
Abstract Number: 1096

A Quality Improvement Project About Medication Adherence to Understand What Questions Rheumatology Patients Have About Their Medications, and How They Answer Them
Abstract Number: 1097

Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program
Abstract Number: 1098

Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Abstract Number: 1099

Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder
Abstract Number: 1100

A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule
Abstract Number: 1101

Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia
Abstract Number: 1102

Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
Abstract Number: 1103

Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].